真实世界研究揭示HER2低表达并非独立预后因素，而是与临床病理特征相关。乳腺癌是全球女性最常见的恶性肿瘤之一。近年来，HER2低表达（HER2-low）乳腺癌作为一种新的治疗亚型备受关注。HER2-low乳腺癌是指HER2免疫组化（IHC）表达为1+ ...

In Europe, approximately 531,000 breast cancer patients are diagnosed annually, with around 141,000 deaths, and around half of all cases would fall under the HER2-low classification, split between ...

The top-line results of DESTINY Breast-04 are impressive - in patients with HER2-low metastatic breast cancer who received multiple lines of prior treatment, Enhertu (trastuzumab deruxtecan ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...

Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer Grafapex (treosulfan) Alkylating agent For use in combination with fludarabine as a preparative regimen for allogeneic ...

In brief, the cancers are: HER2-positive breast cancer unresectable or metastatic HER2-low breast cancer unresectable or metastatic non-small cell lung cancer with activating HER2 mutations ...

Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on the Cleopatra regimen with taxane, Trastuzumab, and Pertuzumab, and 11 ...

Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Low beta stocks are stocks with a low volatility, meaning they are less likely to fluctuate in value. This makes them a less risky investment option ...